In the news: Londoners pioneer new Crohn's drug
Canadians, who suffer some of the world’s highest rates of Crohn’s disease, have a new treatment, thanks to London researchers.
Health Canada has approved a drug called Entyvio that, at least in theory, carries less risk than other front-line drugs because it directly targets inflammation in the digestive tract rather than suppress the immune system throughout the body.
Dr. Brian Feagan, a professor in the Departments of Medicine, and Epidemiology and Biostatistics at the Schulich School of Medicine & Dentistry, and CEO of Robarts Clinical Trials at Robarts Research Institute, led the research efforts.
